1Division of Hematology, Oncology Institute of Southern Switzerland, and.
2Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
J Natl Compr Canc Netw. 2020 Dec 31;19(2):227-233. doi: 10.6004/jnccn.2020.7623.
Genomic instability and clonal heterogeneity can influence cancer progression, response to therapy, and relapse. Chronic lymphocytic leukemia (CLL) harbors a variety of clones and subclones that will evolve differently according to intrinsic (microenvironment) and extrinsic (therapy) pressures. Different patterns of clonal evolution have been described, providing insights into the CLL leukemic cell, dynamics, selection, and treatment refractoriness. With the help of genomic technologies allowing a granular resolution of CLL clones, novel synergic therapeutic strategies can be tested with the aim of reaching a genomic-epigenomic ultrapersonalized, tailored approach. These efforts should consider the presence of targetable alterations, continuous cancer reshaping conferring disease refractoriness, and intratumoral clonal equilibrium to possibly avoid clonal selection.
基因组不稳定性和克隆异质性会影响癌症的进展、对治疗的反应和复发。慢性淋巴细胞白血病 (CLL) 存在多种克隆和亚克隆,它们将根据内在(微环境)和外在(治疗)压力而以不同的方式进化。已经描述了不同的克隆进化模式,为了解 CLL 白血病细胞的动力学、选择和治疗抵抗提供了线索。借助允许对 CLL 克隆进行精细解析的基因组技术,可以测试新的协同治疗策略,旨在实现基于基因组-表观基因组的超个体化、定制化的方法。这些努力应该考虑到靶向改变的存在、持续的癌症重塑导致疾病抵抗以及肿瘤内克隆平衡,以避免可能的克隆选择。